164 related articles for article (PubMed ID: 34687344)
1. Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies.
Luzzago S; Piccinelli ML; Marvaso G; Laukhtina E; Miura N; Schuettfort VM; Mori K; Aydh A; Ferro M; Mistretta FA; Fusco N; Petralia G; Jereczek-Fossa BA; Shariat SF; Karakiewicz PI; de Cobelli O; Musi G
World J Urol; 2022 Feb; 40(2):443-451. PubMed ID: 34687344
[TBL] [Abstract][Full Text] [Related]
2. Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer.
Piccinelli ML; Luzzago S; Marvaso G; Laukhtina E; Miura N; Schuettfort VM; Mori K; Colombo A; Ferro M; Mistretta FA; Fusco N; Petralia G; Jereczek-Fossa BA; Shariat SF; Karakiewicz PI; de Cobelli O; Musi G
World J Urol; 2022 Jun; 40(6):1447-1454. PubMed ID: 35347414
[TBL] [Abstract][Full Text] [Related]
3. Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates.
Luzzago S; Piccinelli ML; Mistretta FA; Bianchi R; Cozzi G; Di Trapani E; Cioffi A; Catellani M; Fontana M; Jannello LMI; Botticelli FMG; Marvaso G; Alessi S; Pricolo P; Ferro M; Matei DV; Jereczek-Fossa BA; Fusco N; Petralia G; de Cobelli O; Musi G
BJU Int; 2022 Apr; 129(4):524-533. PubMed ID: 34687137
[TBL] [Abstract][Full Text] [Related]
4. MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort.
Luzzago S; de Cobelli O; Mistretta FA; Piccinelli ML; Lorusso V; Morelli M; Bianchi R; Catellani M; Cozzi G; Di Trapani E; Pricolo P; Alessi S; Ferro M; Marvaso G; Matei DV; Jereczek-Fossa BA; Petralia G; Musi G
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):406-413. PubMed ID: 32989259
[TBL] [Abstract][Full Text] [Related]
5. Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling.
Luzzago S; Petralia G; Maresca D; Sabatini I; Cordima G; Brescia A; Verweij F; Garelli G; Mistretta FA; Cioffi A; Pricolo P; Alessi S; Ferro M; Matei DV; Renne G; de Cobelli O; Musi G
Urol Oncol; 2020 Dec; 38(12):929.e11-929.e19. PubMed ID: 32600928
[TBL] [Abstract][Full Text] [Related]
6. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
[TBL] [Abstract][Full Text] [Related]
7. Risk and predictors of adverse pathology after radical prostatectomy in patients diagnosed with IUSP 1-2 prostate cancer at MRI-targeted biopsy: a multicenter analysis.
Kesch C; Pantea V; Soeterik T; Marquis A; la Bombarda G; Morlacco A; Barletta F; Radtke JP; Darr C; Preisser F; Zattoni F; Marra G; van den Bergh RCN; Hadaschik B; Gandaglia G;
World J Urol; 2023 Feb; 41(2):427-434. PubMed ID: 36534151
[TBL] [Abstract][Full Text] [Related]
8. Active surveillance in localized prostate cancer: comparison of incidental tumours (T1a/b) and tumours diagnosed by core needle biopsy (T1c/T2a): results from the HAROW study.
Herden J; Wille S; Weissbach L
BJU Int; 2016 Aug; 118(2):258-63. PubMed ID: 26332209
[TBL] [Abstract][Full Text] [Related]
9. Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up.
Luzzago S; Catellani M; Di Trapani E; Cozzi G; Mistretta FA; Bianchi R; Pricolo P; Conti A; Ancona E; Piacentini N; Alessi S; Renne G; Ferro M; Matei DV; Musi G; Jereczek-Fossa BA; Petralia G; de Cobelli O
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):94-101. PubMed ID: 31249386
[TBL] [Abstract][Full Text] [Related]
10. Role of prostate health index to predict Gleason score upgrading and high-risk prostate cancer in radical prostatectomy specimens.
Kim H; Jung G; Kim JH; Byun SS; Hong SK
Sci Rep; 2021 Aug; 11(1):17447. PubMed ID: 34465825
[TBL] [Abstract][Full Text] [Related]
11. Low-volume grade group 2 prostate cancer candidates for active surveillance: a radical prostatectomy retrospective analysis.
Björklund J; Cheung DC; Martin LJ; Komisarenko M; Lajkosz K; Hamilton RJ; Zlotta AR; Finelli A
Scand J Urol; 2023; 57(1-6):29-35. PubMed ID: 36683418
[TBL] [Abstract][Full Text] [Related]
12. "In-bore" MRI prostate biopsy is a safe preoperative clinical tool to exclude significant prostate cancer in symptomatic patients with benign prostatic obstruction before transurethral laser enucleation.
Porreca A; D'Agostino D; Vigo M; Corsi P; Romagnoli D; Del Rosso A; Schiavina R; Brunocilla E; Artibani W; Giampaoli M
Arch Ital Urol Androl; 2020 Jan; 91(4):224-229. PubMed ID: 31937084
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological factors associated with pathological upgrading from biopsy to prostatectomy in patients with ISUP grade group ≤2 prostate cancer.
Li X; Wang ZX; Zhu YP; Wang J; Yin YS; Zeng XY
Asian J Androl; 2022; 24(5):487-493. PubMed ID: 35170453
[TBL] [Abstract][Full Text] [Related]
14. PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.
Lokman U; Erickson AM; Vasarainen H; Rannikko AS; Mirtti T
Eur Urol Focus; 2018 Dec; 4(6):867-873. PubMed ID: 28753869
[TBL] [Abstract][Full Text] [Related]
15. Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.
Singh S; Sandhu P; Beckmann K; Santaolalla A; Dewan K; Clovis S; Rusere J; Zisengwe G; Challacombe B; Brown C; Cathcart P; Popert R; Dasgupta P; Van Hemelrijck M; Elhage O
BJU Int; 2021 Jul; 128(1):72-78. PubMed ID: 33098158
[TBL] [Abstract][Full Text] [Related]
16. Can
Yin H; Chen M; Qiu X; Qiu L; Gao J; Li D; Fu Y; Huang H; Guo S; Zhang Q; Ai S; Wang F; Guo H
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3693-3701. PubMed ID: 33813594
[TBL] [Abstract][Full Text] [Related]
17. Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance.
Ploussard G; Beauval JB; Lesourd M; Almeras C; Assoun J; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
World J Urol; 2020 Mar; 38(3):663-671. PubMed ID: 31197523
[TBL] [Abstract][Full Text] [Related]
18. Predictors of Unfavorable Pathology in Patients with Incidental (pT1a-T1b) Prostate Cancer.
Tsaur I; van den Bergh RCN; Soeterik T; Thomas A; Brandt MP; Zattoni F; Dal Moro F; Morlacco A; Collavino J; Ploussard G; Surcel C; Mirvald C; Carmona O; Rosenzweig B; Ruckes C; Heisinger T; Heidegger I; Gandaglia G; Dotzauer R;
Eur Urol Focus; 2022 Nov; 8(6):1599-1606. PubMed ID: 35317972
[TBL] [Abstract][Full Text] [Related]
19. Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer.
Sanguedolce F; Falagario UG; Castellan P; Di Nauta M; Silecchia G; Bruno SM; Russo D; Treacy PJ; Tewari AK; Montironi R; Carrieri G; Cormio L
Urol Oncol; 2020 Oct; 38(10):793.e19-793.e25. PubMed ID: 32220548
[TBL] [Abstract][Full Text] [Related]
20. Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.
Kaye DR; Qi J; Morgan TM; Linsell S; Ginsburg KB; Lane BR; Montie JE; Cher ML; Miller DC;
BJU Int; 2019 May; 123(5):846-853. PubMed ID: 30248225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
